BioArctic AB (publ) (BIOAB) Earnings Call Transcripts
BioArctic AB (publ)'s Latest Earnings Call - Q1 FY2026
In the first quarter of 2026, BioArctic AB reported revenues of SEK 438 million, reflecting a decline from the previous year primarily due to the absence of a significant upfront payment received in Q1 2025. However, the company's royalty revenue from Leqembi sales grew by 68% year-over-year, indicating strong market demand. Management reiterated their expectation for Leqembi to achieve blockbuster status with projected sales exceeding USD 900 million by 2030, and they maintained a robust cash position of over SEK 2 billion, allowing for continued investment in R&D and potential dividends.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | SEK 438 million (miss) |
| Royalty Revenue | SEK 161 million (beat) |
| Operating Profit | SEK 211 million (inline) |
| Cash Position | SEK 2 billion (positive) |
| Leqembi Sales Forecast | USD 900 million (positive) |
| Q1 R&D Spend | SEK 207 million (negative) |
Guidance from management
Management expects Leqembi to achieve blockbuster status with projected sales exceeding USD 900 million by 2030. They revised R&D cost guidance to increase by 40%-60% in 2026 compared to 2025.
What management said
Yes. So I think what we can say is that we have a broad interest. We have interest both for our drug programs. We have also interest from our BrainTransporter with things that we have done before, and we also have interest in new stuffs that we're working on. So I would say a broad interest.
As for the full year forecast, we can't really comment on that. This is Eisai's forecast, and we believe that they are good and forecasting, and we can't really comment any more than that. As for the Nordics, I hand word to Anna-Kaija.
What analysts pressed on
Analysts expressed concerns regarding the rising R&D costs and the potential impact of regulatory challenges in the Nordic markets on Leqembi's growth. There were also questions about the specifics of the pipeline projects and the timing of upcoming clinical trial results.
Main topics on the call
- Leqembi Sales Growth — Leqembi sales reached EUR 500 million over the last 12 months, with Q1 sales of approximately USD 180 million, nearly doubling from the previous fiscal year. CEO Gunilla Osswald stated, "Leqembi is well on its way to bec...
- R&D Expense Increase — R&D expenses rose significantly due to IND-enabling activities for key projects, particularly in the alpha-synuclein area. CFO Anders Martin-Lof noted, "We expect the cost for 2026 to be roughly 40% to 60% higher compare...
- Regulatory Challenges in Nordic Markets — Management expressed disappointment over a negative recommendation for Leqembi in Sweden, complicating access for patients. Anna-Kaija Gronblad mentioned, "We continue our dialogue with the different stakeholders and aut...
- Pipeline Progress — The alpha-synuclein project exidavnemab is fully recruited for its Phase IIIa study, with results expected later this year. Johanna Fälting highlighted that "the Phase II EXIST study in Parkinson's disease... is now full...
Read the full BioArctic AB (publ) transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About BioArctic AB (publ)
BioArctic AB (publ) (BIOAB) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on OM and is based in SE. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 26 calls on record spanning February 6, 2020 to May 20, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 26 BioArctic AB (publ) earnings call transcripts on record, spanning February 6, 2020 to May 20, 2026. Based on this history, BioArctic AB (publ) reports quarterly. The most recent call on file is dated May 20, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- BIOAB
- Exchange
- OM
- Country
- SE
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 26
- First call
- February 6, 2020
- Most recent
- May 20, 2026
- Reporting cadence
- quarterly